Tata Elxsi launches AI device to assist healthcare corporations get medical software program authorised quicker – CNBC TV18


Tata Elxsi has launched AnaTel, an AI-native software program growth platform for healthcare and medical know-how corporations, co-developed with OpenAna.

The platform was unveiled at DeviceTalks Boston 2026 and is designed to assist software program growth workflows in regulated medical system environments.

In response to the corporate, AnaTel integrates autonomous AI brokers throughout the software program supply lifecycle, together with necessities administration, structure, testing, deployment, verification, validation, and compliance documentation.

The platform additionally helps preparation of regulatory artifacts corresponding to traceability matrices, audit trails, and eSTAR-aligned submissions required beneath evolving FDA and European medical system tips.

Tata Elxsi mentioned the platform is predicted to cut back software-as-a-medical-device (SaMD) growth and alter evaluation timelines from a number of weeks to as little as 72 hours, whereas enhancing productiveness by as much as 60%.

The providing combines Tata Elxsi’s healthcare engineering experience with OpenAna’s autonomous AI engineering platform capabilities.

Sreevatsa Sahasranaman, Senior Vice President and Head, Healthcare and Life Sciences, Tata Elxsi, “AnaTel accelerates regulatory-ready software program engineering by bringing autonomous AI brokers instantly into the event workflows that form compliance and submission readiness, whereas holding our clients’ engineering and regulatory consultants firmly in management.”

Rajiv Sondhi, Chief Govt Officer, OpenAna, “Our mission at OpenAna is to supply autonomous AI brokers that work as dependable co-engineers alongside human groups. Partnering with Tata Elxsi on AnaTel brings this functionality into probably the most demanding domains, regulated healthcare and medtech,
the place lifecycle traceability, security, and compliance are as vital as pace.”

He added that Tata Elxsi’s area experience and AI-first engineering make sure the platform is genuinely contextualized for the regulatory realities medtech groups face daily.

Tata Elxsi shares ended marginally decrease on Wednesday, slipping 0.20% to shut at ₹4,327 on the NSE.

Additionally Learn: Supreme Courtroom upholds 28% GST on on-line gaming; tax notices stand